Full Press Release Details
Herbalife Nutrition Exceeds First Quarter Net Sales Guidance;
Exceeds High End of Reported and Adjusted1 Diluted EPS Guidance
by $0.18 and $0.30, Respectively; Raises Full Year 2018 Guidance
1 Adjusted diluted EPS is a non-GAAP measure and, for the purpose of guidance, excludes the impact of: non-cash interest expense associated with the Company's convertible notes, expenses related to regulatory inquiries, China grant income, contingent value rights revaluation, loss on extinguishment of convertible debt, and Venezuela currency devaluation. Adjusted diluted EPS, for the purpose of reported results, excludes the impact of the foregoing as well as expenses relating to challenges to the Company's business model, and expenses relating to FTC Consent Order implementation. See Schedule A - "Reconciliation of Non-GAAP Financial Measures" for a detailed reconciliation of adjusted net income to net income calculated in accordance with GAAP and a reconciliation of adjusted diluted EPS to diluted EPS calculated in accordance with GAAP and a discussion of why we believe these non-GAAP measures are useful.
First Quarter 2018 Key Metrics2
Regional Volume Point Metrics
| Volume Points | ||
| Region | 1Q '18 (mil) | Yr/Yr % Chg |
| North America | 303.2 | 0.2% |
| Mexico | 221.8 | (1.6%) |
| South & Central America | 148.5 | (3.1%) |
| EMEA | 294.7 | 7.5% |
| Asia Pacific | 286.6 | 9.9% |
| China | 141.1 | (22.5%) |
| Worldwide Total (a) | 1,395.9 | (0.2%) |
(a) During the quarter, the Company adjusted volume point values for certain products in Mexico and South & Central America. Excluding these adjustments, the volume point decrease would have been (0.5%).
Regional Net Sales and Foreign Exchange ("FX") Impact
| Region | Reported Net Sales 1Q'18 (mil) | Growth/Decline including FX vs. 1Q 17 | Growth/Decline excluding FX vs. 1Q 17 | |||||||||
| North America | $ | 231.2 | 0.6 | % | 0.5 | % | ||||||
| Mexico | $ | 114.0 | 8.8 | % | 0.4 | % | ||||||
| South & Central America (a) | $ | 125.7 | 2.7 | % | 57.3 | % | ||||||
| EMEA | $ | 248.2 | 18.3 | % | 6.9 | % | ||||||
| Asia Pacific | $ | 245.6 | 11.8 | % | 7.6 | % | ||||||
| China | $ | 212.2 | (1.6 | %) | (9.2 | %) | ||||||
| Worldwide Total | $ | 1,176.9 | 6.8 | % | 7.5 | % | ||||||
| South & Central America excl . Venezuela (a) | $ | 119.0 | (0.6 | %) | 1.5 | % | ||||||
| Worldwide Total excl . Venezuela (a) | $ | 1,170.2 | 6.4 | % | 1.4 | % |
(a) Venezuela was impacted by significant price increases and erosion in foreign currency exchange rates. Venezuela represents less than 1% of consolidated net sales. See Schedule A - "Reconciliation of Non-GAAP Financial Measures" for a discussion of why we believe adjusting for Venezuela is useful.
2 Supplemental tables that include Average Active Sales Leader and additional business metrics can be found at http://ir.Herbalife.com.
Following is the Company's second quarter 2018 and full year 2018 guidance based on current business trends:
| Three Months Ending | Twelve Months Ending | |||||||||||||||
| June 30, 2018 | December 31, 2018 | |||||||||||||||
| Low | High | Low | High | |||||||||||||
| Volume Point Growth vs 2017 (a) | 4.0 | % | 8.0 | % | 3.0 | % | 7.0 | % | ||||||||
| Net Sales Growth vs 2017 (b) | 8.5 | % | 12.5 | % | 9.0 | % | 13.0 | % | ||||||||
| Diluted EPS - Pre Stock Split (b) (c) (e) | $ | 0.90 | $ | 1.10 | $ | 3.95 | $ | 4.35 | ||||||||
| Adjusted Diluted EPS - Pre Stock Split (b) (c) (d) (e) | $ | 1.15 | $ | 1.35 | $ | 5.05 | $ | 5.45 | ||||||||
| Diluted EPS - Post Stock Split (b) (c) (e) | $ | 0.45 | $ | 0.55 | $ | 1.98 | $ | 2.18 | ||||||||
| Adjusted Diluted EPS - Post Stock Split (b) (c) (d) (e) | $ | 0.58 | $ | 0.68 | $ | 2.53 | $ | 2.73 | ||||||||
| Cap Ex ($ millions) | $ | 25.0 | $ | 35.0 | $ | 110.0 | $ | 140.0 | ||||||||
| Effective Tax Rate (b) (c) | 36.0 | % | 41.0 | % | 30.0 | % | 35.0 | % | ||||||||
| Adjusted Effective Tax Rate (b) (c) (d) | 29.0 | % | 34.0 | % | 23.0 | % | 28.0 | % |
(a) Management is evaluating our current approach to assigning and maintaining Volume Point values for certain products or markets. Guidance excludes any future potential impact of Volume Point adjustments, which may have an impact on the use of Volume Points as a proxy for sales trends in future periods.
(b) Excludes any future potential Venezuela currency devaluations and associated pricing and inflationary consequences.
(c) Excludes the following items that cannot be accurately predicted: any future potential ongoing tax effects from the exercise of equity awards that could impact the Company's tax rate due to the updated stock compensation accounting standard, any future contingent value rights revaluation, benefits from future potential China grant income, any future potential dilution from the Company's convertible notes due in 2019 and 2024, as well as any impact of the China Growth and Impact Investment Program.
(d) Adjusted diluted EPS and adjusted effective tax rate excludes the impact of: non-cash interest expense associated with the Company's convertible notes, expenses related to regulatory inquiries, China grant income, contingent value rights revaluation, loss on extinguishment of convertible debt, Venezuela currency devaluation, as well as any impact of the China Growth and Impact Investment Program, as detailed in Schedule A. See Schedule A - "Reconciliation of Non-GAAP Financial Measures" for a detailed reconciliation of adjusted diluted EPS to diluted EPS calculated in accordance with GAAP and a discussion of why the company believe these non-GAAP measures are useful.
(e) Shareholders recently approved a two-for-one stock split with a record date of May 7, 2018. For the purposes of guidance the Company has provided Diluted EPS on both a pre and post stock split basis.
Earnings Conference Call
Herbalife Nutrition senior management will host an investor conference call to discuss its recent financial results and provide an update on current business trends on Thursday, May 3, 2018, at 2:30 p.m. PT (5:30 p.m. ET).
The dial-in number for this conference call for domestic callers is (877) 317-1296, and (262) 320-2006 for international callers (conference ID: 6562099). Live audio of the conference call will be simultaneously webcast in the investor relations section of the Company's website at http://ir.Herbalife.com.
An audio replay will be available following the completion of the conference call in MP3 format or by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers (conference ID: 6562099). The webcast of the teleconference will be archived and available on Herbalife Nutrition's website.
About Herbalife Nutrition Ltd.
Herbalife Nutrition is a global nutrition company whose purpose is to make the world healthier and happier. The Company has been on a mission for nutrition - changing people's lives with great nutrition products & programs - since 1980. Together with our Herbalife Nutrition independent distributors, we are committed to providing solutions to the worldwide problems of poor nutrition and obesity, an aging population, and skyrocketing public healthcare costs, while supporting the rise in entrepreneurs of all ages. Herbalife Nutrition offers high-quality, science-backed products, most of which are produced in Company-operated facilities, one-on-one coaching with an Herbalife Nutrition independent distributor, and a supportive community approach that inspires customers to embrace a healthier, more active lifestyle.
Herbalife Nutrition's targeted nutrition, weight-management, energy and fitness and personal care products are available exclusively to and through dedicated Herbalife Nutrition distributors in more than 90 countries.
Through its corporate social responsibility efforts, Herbalife Nutrition supports the Herbalife Family Foundation (HFF) and its Casa Herbalife Nutrition programs to help bring good nutrition to children in need. Herbalife Nutrition is also proud to sponsor more than 190 world-class athletes, teams and events around the globe, including Cristiano Ronaldo, the LA Galaxy, and numerous Olympic teams.
Herbalife Nutrition has over 8,000 employees worldwide, and its shares are traded on the New York Stock Exchange (NYSE: HLF) with net sales of approximately $4.4 billion in 2017. To learn more, visit Herbalife.com or IAmHerbalife.com.
Herbalife Nutrition also encourages investors to visit its investor relations website at ir.Herbalife.com as financial and other information is updated and new information is posted.
Director, Investor Relations
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, such as those disclosed or incorporated by reference in our filings with the Securities and Exchange Commission. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in our forward-looking statements include, among others, the following:
We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Results of Operations
| Herbalife Nutrition Ltd. and Subsidiaries | ||||||||
| Condensed Consolidated Statements of Income | ||||||||
| (In millions, except per share amounts) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended | ||||||||
| 3/31/2018 | 3/31/2017 | |||||||
| North America | $ | 231.2 | $ | 229.8 | ||||
| Mexico | 114.0 | 104.8 | ||||||
| South and Central America | 125.7 | 122.4 | ||||||
| EMEA | 248.2 | 209.8 | ||||||
| Asia Pacific | 245.6 | 219.7 | ||||||
| China | 212.2 | 215.6 | ||||||
| Worldwide Net Sales | 1,176.9 | 1,102.1 | ||||||
| Cost of Sales | 239.9 | 204.6 | ||||||
| Gross Profit | 937.0 | 897.5 | ||||||
| Royalty Overrides | 337.3 | 315.1 | ||||||
| Selling, General and Administrative Expenses | 460.1 | 438.6 | ||||||
| Other Operating Income (1) | (16.2 | ) | - | |||||
| Operating Income | 155.8 | 143.8 | ||||||
| Interest Expense, net | 39.9 | 30.2 | ||||||
| Other Expense, net (2) | 24.4 | - | ||||||
| Income Before Income Taxes | 91.5 | 113.6 | ||||||
| Income Taxes (3) | 9.4 | 28.4 | ||||||
| Net Income | $ | 82.1 | $ | 85.2 | ||||
| Weighted Average Shares Outstanding: | ||||||||
| Basic | 72.7 | 83.1 | ||||||
| Diluted | 76.3 | 86.7 | ||||||
| Earnings Per Share: | ||||||||
| Basic | $ | 1.13 | $ | 1.03 | ||||
| Diluted | $ | 1.08 | $ | 0.98 |
| (1) Other Operating Income relates to certain China government grant income. |
| (2) Other Expense relates to the loss on revaluation of the Contingent Value Rights issued in connection with the October 2017 modified Dutch auction tender offer and loss on the extinguishment of a portion of the 2.0% convertible senior notes due 2019 repurchased in March 2018. |
| (3) Includes the impact of excess tax benefit recognized under ASU 2016-09 of $19.4 million and $4.3 million for the three months ended March 31, 2018 and 2017, respectively. |
| Herbalife Nutrition Ltd. and Subsidiaries | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (In millions) | ||||||||
| (Unaudited) | ||||||||
| Mar 31, | Dec 31, | |||||||
| 2018 | 2017 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 1,330.2 | $ | 1,278.8 | ||||
| Receivables, net | 103.3 | 93.3 | ||||||
| Inventories | 333.0 | 341.2 | ||||||
| Prepaid expenses and other current assets | 184.6 | 147.0 | ||||||
| Total Current Assets | 1,951.1 | 1,860.3 | ||||||
| Property, plant and equipment, net | 369.2 | 377.5 | ||||||
| Marketing related intangibles and other intangible assets, net | 310.1 | 310.1 | ||||||
| Goodwill | 98.6 | 96.9 | ||||||
| Other assets | 239.7 | 250.3 | ||||||
| Total Assets | $ | 2,968.7 | $ | 2,895.1 | ||||
| LIABILITIES AND SHAREHOLDERS' DEFICIT | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 80.2 | $ | 67.8 | ||||
| Royalty overrides | 264.7 | 277.7 | ||||||
| Current portion of long-term debt | 102.3 | 102.4 | ||||||
| Other current liabilities | 463.7 | 458.9 | ||||||
| Total Current Liabilities | 910.9 | 906.8 | ||||||
| Non-current liabilities | ||||||||
| Long-term debt, net of current portion | 2,109.1 | 2,165.7 | ||||||
| Other non-current liabilities | 167.7 | 157.3 | ||||||
| Total Liabilities | 3,187.7 | 3,229.8 | ||||||
| Commitments and Contingencies | ||||||||
| Shareholders' deficit: | ||||||||
| Common shares | 0.1 | 0.1 | ||||||
| Paid-in capital in excess of par value | 425.4 | 407.3 | ||||||
| Accumulated other comprehensive loss | (147.3 | ) | (165.4 | ) | ||||
| Accumulated deficit | (168.3 | ) | (248.1 | ) | ||||
| Treasury stock | (328.9 | ) | (328.6 | ) | ||||
| Total Shareholders' Deficit | (219.0 | ) | (334.7 | ) | ||||
| Total Liabilities and Shareholders' Deficit | $ | 2,968.7 | $ | 2,895.1 |
| Herbalife Nutrition Ltd. and Subsidiaries | ||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (In millions) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended | ||||||||
| 3/31/2018 | 3/31/2017 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net income | $ | 82.1 | $ | 85.2 | ||||
| Adjustments to reconcile net income to net cash provided by | ||||||||
| operating activities: | ||||||||
| Depreciation and amortization | 25.6 | 24.5 | ||||||
| Share-based compensation expenses | 9.8 | 11.3 | ||||||
| Non-cash interest expense | 15.7 | 14.4 | ||||||
| Deferred income taxes | 3.3 | (3.2 | ) | |||||
| Inventory write-downs | 12.1 | 4.6 | ||||||
| Foreign exchange transaction loss (gain) | 0.5 | (0.4 | ) | |||||
| Other | 25.5 | (1.0 | ) | |||||
| Changes in operating assets and liabilities: | ||||||||
| Receivables | (16.1 | ) | (27.9 | ) | ||||
| Inventories | 8.4 | 7.3 | ||||||
| Prepaid expenses and other current assets | (11.9 | ) | 25.1 | |||||
| Accounts payable | 16.4 | 5.0 | ||||||
| Royalty overrides | (12.6 | ) | (18.8 | ) | ||||
| Other current liabilities | (3.7 | ) | 44.6 | |||||
| Other | 1.1 | 4.8 | ||||||
| NET CASH PROVIDED BY OPERATING ACTIVITIES | 156.2 | 175.5 | ||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of property, plant and equipment | (15.6 | ) | (24.5 | ) | ||||
| Other | - | 0.1 | ||||||
| NET CASH USED IN INVESTING ACTIVITIES | (15.6 | ) | (24.4 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Borrowings from senior secured credit facility, net of discount | - | 1,274.0 | ||||||
| Principal payments on senior secured credit facility and other debt | (24.5 | ) | (413.4 | ) | ||||
| Proceeds from senior convertible notes | 550.0 | - | ||||||
| Repurchase of senior convertible notes | (582.5 | ) | - | |||||
| Debt issuance costs | (11.7 | ) | (22.6 | ) | ||||
| Share repurchases | (54.2 | ) | (58.1 | ) | ||||
| Proceeds from settlement of capped call transactions | 27.1 | - | ||||||
| Other | 0.6 | 0.6 | ||||||
| NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES | (95.2 | ) | 780.5 | |||||
| EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | 6.1 | 9.1 | ||||||
| NET CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | 51.5 | 940.7 | ||||||
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF PERIOD | 1,295.5 | 857.0 | ||||||
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, END OF PERIOD | $ | 1,347.0 | $ | 1,797.7 |
Supplemental Information
SCHEDULE A: RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(Unaudited and unreviewed), (All tables provide Dollars in millions, except per Share Data)
In addition to its reported results and guidance calculated in accordance with GAAP, the Company has included in this release adjusted net income and adjusted diluted EPS, performance measures that the Securities and Exchange Commission defines as "non-GAAP financial measures." Management believes that such non-GAAP financial measures, when read in conjunction with the Company's reported or forecasted results, in each case calculated in accordance with GAAP, can provide useful supplemental information for investors because they facilitate a period to period comparative assessment of the Company's operating performance relative to its performance based on reported or forecasted results under GAAP, while isolating the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company's operations and underlying operational performance. The Company's definition of adjusted net income and adjusted diluted earnings per share may not be comparable to similarly titled measures used by other companies because other companies may not calculate them in the same manner as the Company does and should not be viewed in isolation from nor as alternatives to net income or diluted EPS calculated in accordance with GAAP.
The impact of foreign currency fluctuations in Venezuela and the price increases we implement as a result of the highly inflationary economy in that market can each, when considered in isolation, have a disproportionately large impact to our consolidated results despite the offsetting nature of these drivers and that net sales in Venezuela, which represent less than 1% of our consolidated net sales, are not material to our consolidated results. Therefore, in certain instances, we believe it is helpful to provide additional information with respect to these factors as reported and excluding the impact of Venezuela to illustrate the disproportionate nature of Venezuela's individual pricing and foreign exchange impact to our consolidated results. However, excluding the impact of Venezuela from these measures is not in accordance with U.S. GAAP and should not be considered in isolation or as an alternative to the presentation and discussion thereof calculated in accordance with U.S. GAAP.
The following is a reconciliation of net income, presented and reported in accordance with U.S. generally accepted accounting principles, to net income adjusted for certain items:
| Three Months Ended | ||||||||
| 3/31/2018 | 3/31/2017 | |||||||
| (in millions) | ||||||||
| Net income, as reported | $ | 82.1 | $ | 85.2 | ||||
| Expenses incurred responding to attacks on the Company's business model (1) (2) | - | 1.5 | ||||||
| Expenses related to regulatory inquiries (1) (2) | 2.3 | 3.8 | ||||||
| Non-cash interest expense and amortization of non-cash issuance costs (1) (2) (3) | 12.5 | 11.7 | ||||||
| China grant income (1) (2) | (16.2 | ) | - | |||||
| FTC Consent Order implementation (1) (2) (4) | - | 8.5 | ||||||
| Contingent value rights revaluation (1) (2) | 11.3 | - | ||||||
| Loss on extinguishment of convertible debt (1) (2) (5) | 13.1 | - | ||||||
| Venezuela devaluation (1) (2) | 4.7 | - | ||||||
| Income tax adjustments for above items (1) (2) | (3.3 | ) | (3.5 | ) | ||||
| Net income, as adjusted (6) | $ | 106.5 | $ | 107.1 |
The following is a reconciliation of diluted earnings per share, presented and reported in accordance with U.S. generally accepted accounting principles, to diluted earnings per share adjusted for certain items.
| Three Months Ended | ||||||||
| 3/31/2018 | 3/31/2017 | |||||||
| (per share) | ||||||||
| Diluted earnings per share, as reported | $ | 1.08 | $ | 0.98 | ||||
| Expenses incurred responding to attacks on the Company's business model (1) (2) | - | 0.02 | ||||||
| Expenses related to regulatory inquiries (1) (2) | 0.03 | 0.04 | ||||||
| Non-cash interest expense and amortization of non-cash issuance costs (1) (2) (3) | 0.16 | 0.13 | ||||||
| China grant income (1) (2) | (0.21 | ) | - | |||||
| FTC Consent Order implementation (1) (2) (4) | - | 0.10 | ||||||
| Contingent value rights revaluation (1) (2) | 0.15 | - | ||||||
| Loss on extinguishment of convertible debt (1) (2) (5) | 0.17 | - | ||||||
| Venezuela devaluation (1) (2) | 0.06 | - | ||||||
| Income tax adjustments for above items (1) (2) | (0.04 | ) | (0.04 | ) | ||||
| Diluted earnings per share, as adjusted (6) | $ | 1.40 | $ | 1.24 |
| (2) Excludes tax (benefit)/expense as follows: | ||||||||
| Three Months Ended | ||||||||
| 3/31/2018 | 3/31/2017 | |||||||
| (in millions) | ||||||||
| Expenses incurred responding to attacks on the Company's business model | $ | - | $ | (0.4 | ) | |||
| Expenses related to regulatory inquiries | (0.2 | ) | (1.3 | ) | ||||
| Non-cash interest expense and amortization of non-cash issuance costs | (0.3 | ) | 0.9 | |||||
| China grant income | 5.8 | - | ||||||
| FTC Consent Order Implementation | - | (2.8 | ) | |||||
| Contingent Value Rights revaluation | (3.3 | ) | - | |||||
| Loss on extinguishment of convertible debt | (3.7 | ) | - | |||||
| Venezuela devaluation | (1.6 | ) | - | |||||
| Total income tax adjustments (6) | $ | (3.3 | ) | $ | (3.5 | ) | ||
| Three Months Ended | ||||||||
| 3/31/2018 | 3/31/2017 | |||||||
| (per share) | ||||||||
| Expenses incurred responding to attacks on the Company's business model | $ | - | $ | - | ||||
| Expenses related to regulatory inquiries | - | (0.01 | ) | |||||
| Non-cash interest expense and amortization of non-cash issuance costs | - | 0.01 | ||||||
| China grant income | 0.08 | - | ||||||
| FTC Consent Order Implementation | - | (0.03 | ) | |||||
| Contingent Value Rights revaluation | (0.04 | ) | - | |||||
| Loss on extinguishment of convertible debt | (0.05 | ) | - | |||||
| Venezuela devaluation | (0.02 | ) | - | |||||
| Total income tax adjustments (6) | $ | (0.04 | ) | $ | (0.04 | ) |
| (3) Relates to non-cash expense on the Company's 2.00% convertible senior notes due 2019 and the related prepaid forward share repurchase contract and the 2.625% convertible senior notes due 2024. |
| (4) Includes $3.0 million of product discounts related to preferred member conversions for the three months ended March 31, 2017. |
| (5) Relates to the loss on the extinguishment of a portion of the 2.00% convertible senior notes due 2019 repuruchased in March 2018. |
| (6) Amounts may not total due to rounding. |
The following is a reconciliation of diluted earnings per share guidance, presented in accordance with U.S. generally accepted accounting principles, to adjusted diluted earnings per share guidance for certain items.
| Three Months Ending | Twelve Months Ending | |||||||
| June 30, 2018 | December 31, 2018 | |||||||
| Diluted EPS Guidance (1) | $ | 0.90 - $1.10 | $ | 3.95 - $4.35 | ||||
| Non-cash interest expense and amortization of non-cash issuance costs (2) | 0.17 | 0.69 | ||||||
| Expenses related to regulatory inquiries (3) | 0.04 | 0.16 | ||||||
| China Grant Income (4) | - | (0.22 | ) | |||||
| Contingent value rights revaluation (5) | - | 0.16 | ||||||
| Loss on extinguishment of convertible debt (6) | - | 0.18 | ||||||
| Venezuela devaluation (7) | - | 0.06 | ||||||
| Income tax adjustments for above items (8) | 0.03 | 0.07 | ||||||
| Adjusted Diluted EPS Guidance (9) | $ | 1.15 - $1.35 | $ | 5.05 - $5.45 |
| (1) Excludes any future potential ongoing tax effects from the exercise of equity awards that could impact the Company's tax rate due to the updated stock compensation accounting standard, any future contingent value rights revaluation, benefits from future potential China grant income, any future potential dilution from the Company's convertible notes, any future potential Venezuela currency devaluations and associated pricing and inflationary consequences, as well as any impact of the China Growth and Impact Investment Program. |
| (2) Relates to non-cash expense on the Company's 2.00% convertible senior notes due 2019 and the related prepaid forward share repurchase contract and the 2.625% convertible notes due 2024. |
| (3) Excludes tax impact of $0.3 million and $1.1 million for the three months ending June 30, 2018 and the twelve months ending December 31, 2018, respectively. |
| (4) Excludes tax impact of $0.4 million and $4.7 million for the three months ending June 30, 2018 and the twelve months ending December 31, 2018, respectively. |
| (5) Relates to the loss on the extinguishment of a portion of the 2.00% convertible senior notes due 2019 repuruchased in March 31, 2018 and excludes tax impact of $1.1 million for the three months ending June 30, 2018. |
| (6) Excludes tax impact of $1.2 million for the three months ending June 30, 2018. |
| (7) Excludes tax impact of $0.2 million and $1.1 million for the three months ending June 30, 2018 and the twelve months ending December 31, 2018, respectively. |
| (8) Aggregates the individual tax impacts of each item as described in greater detail in footnotes 3 through 7 above. |
| (9) Amounts may not total due to rounding. |